Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.
- Farge, D.
- Passweg, J.R.
- Laar, J.M. van
- Marjanovic, Z.
- Besenthal, C.
- Finke, J.
- Peter, H.H.
- Breedveld, F.C.
- Fibbe, W.
- Black, C.
- Denton, C.
- Koetter, I.
- Locatelli, F.
- Martini, A.
- Schattenberg, A.V.M.B.
- Hoogen, F.H.J. van den
- Putte, L.B.A. van de
- Lanza, F.
- Arnold, R.
- Bacon, P.A.
- Bingham, S.
- Ciceri, F.
- Didier, B.
- Diez-Martin, J.L.
- Emery, P.
- Feremans, W.
- Hertenstein, B.
- Hiepe, F.
- Luosujarvi, R.
- Leon Lara, A.
- Marmont, A.
- Martinez, A.
- Pascual Cascon, H.
- Bocelli-Tyndall, C.
- Gluckman, E.
- Gratwohl, A.
- Tyndall, A.
DOIAbstract
Contains fulltext : 58256schattenberg.pdf (publisher's version ) (Closed access)OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-respo...
Add to ORKG